Galectin-9 alleviates acute graft-versus-host disease after haplo-hematopoietic stem cell transplantation by regulating regulatory T cell/effector T cell imbalance.

Nannan PangShabaaiti TudahongYuejie ZhuJiang HeChunxia HanGang ChenWeiguo WangJing Wang Jianbing Ding

Published in: Immunity, inflammation and disease (2024)

Galectin-9 may ameliorate aGVHD after haplo-HSCT by modulating Treg/Teffs balance and regulating the PI3K/AKT/mTOR pathway. Targeting Galectin-9 may hold potential value for the treatment of aGVHD.

Keyphrases

liver failure
acute myeloid leukemia
dendritic cells
transcription factor
signaling pathway
respiratory failure
regulatory t cells
cancer therapy
immune response
intensive care unit
combination therapy
drug delivery
human health